

Resource Summary Report

Generated by [RRID](#) on Jul 29, 2026

APC anti-mouse CD3

RRID:AB_2561455

Type: Antibody

Proper Citation

BioLegend Cat# 100235, RRID:AB_2561455

Antibody Information

URL: http://antibodyregistry.org/AB_2561455

Proper Citation: BioLegend Cat# 100235, RRID:AB_2561455

Target Antigen: CD3

Host Organism: rat

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: APC anti-mouse CD3

Description: This monoclonal targets CD3

Target Organism: mouse

Clone ID: Clone 17A2

Antibody ID: AB_2561455

Vendor: BioLegend

Catalog Number: 100235

Alternative Catalog Numbers: 100236

Record Creation Time: 20250820T024500+0000

Record Last Update: 20250820T142515+0000

Ratings and Alerts

No rating or validation information has been found for APC anti-mouse CD3.

No alerts have been found for APC anti-mouse CD3.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 65 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Avanessian SC, et al. (2026) IL2/IL15 Signaling Induces NK Cell Production of FLT3LG, Augmenting Anti-PD-1 Immunotherapy. *Cancer immunology research*, 14(1), 122.

Lee W, et al. (2025) Neutrophil extracellular traps promote pre-metastatic niche formation in the omentum by expanding innate-like B cells that express IL-10. *Cancer cell*, 43(1), 69.

Cohen SJ, et al. (2025) Liver microbial DNA signatures and extracellular vesicle epitopes as predictors of post-hepatectomy liver failure. *iScience*, 28(10), 113618.

Henriques-Oliveira L, et al. (2025) Anchored screening identifies transcription factor blueprints underlying dendritic cell diversity and subset-specific anti-tumor immunity. *Immunity*.

Mengrelis K, et al. (2025) IL-2 Complex Therapy Mitigates Humoral Rejection of Fully Mismatched Skin Allografts by Inhibiting IgG Alloantibody Formation. *Cells*, 14(14).

Young RE, et al. (2025) Disruption of E-cadherin in the airway led to dysplastic stressed cells and asthma-like phenotypes. *Developmental cell*.

Emelianov EA, et al. (2025) Pre-Treatment with Dacarbazine Sensitizes B16 Melanoma to CAR T Cell Therapy in Syngeneic Mouse Model. *International journal of molecular sciences*, 27(1).

Zhang Z, et al. (2025) Cardiolipin-mimic lipid nanoparticles without antibody modification delivered senolytic in vivo CAR-T therapy for inflamm-aging. *Cell reports. Medicine*, 6(7), 102209.

Zeng Q, et al. (2025) ORMDL3 restrains type I interferon signaling and anti-tumor immunity by promoting RIG-I degradation. *eLife*, 13.

Nyberg WA, et al. (2025) In vivo engineering of murine T cells using the evolved adeno-associated virus variant Ark313. *Immunity*, 58(2), 499.

Gao C, et al. (2025) Cancer vaccine from intracellularly gelated tumor cells functionalized with CD47 blockage and damage-associated molecular pattern exposure. *Cell reports. Medicine*, 6(5), 102092.

Nagahashi M, et al. (2025) An Acrolein-Based Drug Delivery System Enables Tumor-Specific Sphingosine-1-Phosphate Targeting in Breast Cancer without Lymphocytopenia. *Cancer research communications*, 5(6), 981.

He J, et al. (2025) Potentiating immunotherapy in "immune-cold" solid tumors through orchestrating T cell immunity via tumor-specific genetic engineering. *Cell reports. Medicine*, 6(12), 102510.

Matoba K, et al. (2025) Circulating extracellular vesicle microRNAs mediate immune modulation of social behavior in mice. *bioRxiv : the preprint server for biology*.

Chen Z, et al. (2025) YTHDF2 promotes ATP synthesis and immune evasion in B cell malignancies. *Cell*, 188(2), 331.

Van Roy Z, et al. (2025) Interferon-gamma receptor signaling regulates innate immunity during *Staphylococcus aureus* craniotomy infection. *Journal of neuroinflammation*, 22(1), 46.

Cheng JN, et al. (2025) Bone metastases diminish extraosseous response to checkpoint blockade immunotherapy through osteopontin-producing osteoclasts. *Cancer cell*, 43(6), 1093.

Zhou S, et al. (2025) Indole-3-lactic acid suppresses colorectal cancer via metabolic reprogramming. *Gut microbes*, 17(1), 2508949.

Zhang FQ, et al. (2025) Zeaxanthin augments CD8⁺ effector T cell function and immunotherapy efficacy. *Cell reports. Medicine*, 6(9), 102324.

Li Z, et al. (2024) Nanodrug-bacteria conjugates-mediated oncogenic collagen depletion enhances immune checkpoint blockade therapy against pancreatic cancer. *Med (New York, N.Y.)*, 5(4), 348.